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A promising new strategy for monitoring EPP therapy  
Erythropoietic protoporphyria (EPP) is a rare inherited disorder characterised by acute 
photosensitivity that often presents in early childhood. EPP has been reported worldwide, with the 
estimated Scottish and UK prevalences being 1:43,5001 and 1:143,0002 respectively. EPP was first 
described in 1961,3 and is caused by mutations in ferrochelatase (FECH), the enzyme that catalyses 
iron insertion into protoporphyrin IX (PPIX) to form haem. Reduced ferrochelatase activity results in 
PPIX accumulation in the skin, blood cells and skin blood vessels that causes stinging, tingling, 
burning or prickling upon sun exposure and which can persist for many days. This painful phototoxic 
reaction is rarely responsive to analgesia meaning that EPP patients are often fearful of the sun with 
a significant impact on quality of life. Many patients also experience a ‘priming phenomenon’ in 
which sunlight exposure primes the skin so that shorter periods of subsequent sun exposure cause 
symptoms.4 
Whilst a number of therapies have been trialled for EPP, difficulties in objective assessment of 
disease activity and dependence on patient self-assessment, which is highly susceptible to the 
placebo effect, has meant that treatment efficacy is often unclear.5,6 Being able to monitor the 
effectiveness of EPP treatments would provide much-needed clarity on their benefits and would 
represent a huge advance in the field.  
In this issue of the BJD, Heerfordt and Wulf describe a method for dynamically measuring PPIX levels 
in the skin of EPP patients which could be used to monitor treatment efficacy by comparing the light 
dose required to elicit symptoms before and after treatment. In contrast to previous measurements 
of skin PPIX which relied on biopsies or inducing blister formation,7 the authors used a fluorescence 
photometer which has previously been used to measure methyl-aminolaevulinate (MAL) induced 
PPIX accumulation in photodynamic therapy8 to measure skin PPIX levels before and after PPIX 
photobleaching. By analysing skin PPIX alongside erythrocyte PPIX, the authors could correlate the 
level of skin PPIX with erythrocyte PPIX concentration as well as the pain and erythema induced by 
light. Their results confirm for the first time that high skin (or erythrocyte) PPIX levels are associated 
with an increased likelihood of photosensitivity in EPP patients.  
By monitoring the dynamics of skin PPIX levels following illumination, their analysis also provides 
interesting insights into photopriming. EPP patients with high initial skin PPIX were more likely to 
have increased PPIX in their skin the day after illumination, although the speed of accumulation 
differed between patients. This may be attributable to differences in the rates of initial light induced 
PPIX leakage from erythrocytes and subsequent release from damaged blood vessels and endothelial 
cells, although it would be interesting to explore this further since modulating the release of PPIX 
could represent a viable therapeutic strategy.    
Taken together, this important research helps explain why the sunlight tolerance of EPP patients 
varies both between patients and within the same patient from day-to-day,4 and applying this much-
needed new method to interrogate the effectiveness of EPP treatments will be valuable.  
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